| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532; 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:Halofuginone Hydrochloride
CAS:1217623-74-9
Package:10Mg,1Mg
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Halofuginone Hydrochloride
CAS:1217623-74-9
Purity:>95%
|
|
| | Halofuginone Hydrochloride Basic information |
| | Halofuginone Hydrochloride Chemical Properties |
| Melting point | 247-249°C (dec.) | | storage temp. | -20°C Freezer, Under Inert Atmosphere | | solubility | DMSO: soluble; Water: soluble | | form | A crystalline solid |
| | Halofuginone Hydrochloride Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | Halofuginone is a halogenated derivative of Febrifugine (F228500). Halofuginone is used as an antiprotozoal. | | Uses | Halogenated derivative of Febrifugine. Used as an antiprotozoal. | | in vivo | Halofuginone hydrobromid (0.2, 0.5, 1 or 2.5 mg/kg; injected intraperitoneally every other day for 1 month) attenuates progression of OA in anterior cruciate ligament transection (ACLT) mice. Lower concentration (0.2 or 0.5 mg/kg) has minimal effects on subchondral bone and higher concentration (2.5 mg/kg) induces proteoglycan loss in articular cartilage[3].
Halofuginone hydrobromid (0.25 mg/kg; intraperitoneally injected; every day; 16 days) decreases NRF2 protein levels in tumors. While the tumor volumes do not change substantially between treatments with the vehicle, Halofuginone hydrobromid (0.25 mg/kg, intraperitoneally injected, every day) or cisplatin alone. Combined treatment with Halofuginone and Cisplatin significantly suppresses the tumor volume compared to treatment with Halofuginone or cisplatin alone[1].
Intraperitoneal hydrobromid administration of Halofuginone (0.3mg/kg, for 2 weeks) partially reverses the established pulmonary hypertension in mice[5]. | Animal Model: | 3-month-old male C57BL/6J (WT) mice[3] | | Dosage: | 0.2, 0.5, 1 or 2.5 mg/kg | | Administration: | Injected intraperitoneally every other day for 1 month | | Result: | Attenuated progression of OA in ACLT mice. |
| Animal Model: | Male nude mice (BALB/C nu/nu mice) (6-8-week)[1] | | Dosage: | 0.25 mg/kg | | Administration: | Intraperitoneally injected; every day; 16 days | | Result: | The combined treatment with Cisplatin significantly suppressed the tumor volume. NRF2 protein levels in tumors were indeed decreased. |
|
| | Halofuginone Hydrochloride Preparation Products And Raw materials |
|